Skip to main content
Premium Trial:

Request an Annual Quote

Samuel Riccitelli, David Cohen

Precipio has appointed Samuel Riccitelli as chairman, replacing Robert Patzig who resigned after seven years on the board of Transgenomic, which recently merged with Precipio. Also, David Cohen was elected as a new director at Precipio to fill an existing vacancy. 

Riccitelli has been on Precipio's board since June. From October 2012 through February 2017, he was president and CEO of Signal Genetics, where he also was a director. Before that, he was executive vice president and COO of Genoptix.

Cohen is COO and co-owner of Standard Oil of Connecticut, and has founded several ventures, including My Gene Counsel, a cancer bioinformatics company.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.